StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)

Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%

Pfizer Collaborative arrangements by Year

Collaborative arrangements — Net R&D development cost-sharing ($M) ($M)

Pfizer Collaborative arrangements: -$145M in FY2025, down 48.6% from a year earlier.

Latest, FY2025
-145
Period ended Dec 31, 2025
Change on a year earlier
-48.6%
-282 in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-26) ↗

Reported in Form 10-K Collaborative Arrangements Footnote.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCollaborative arrangements — Net R&D development cost-sharing ($M) ($M)Year on yearSource
FY2025Dec 31, 2025-145-48.6%Form 10-K (filed 2026-02-26) ↗
FY2024Dec 31, 2024-282+28.8%Form 10-K (filed 2026-02-26) ↗
FY2023Dec 31, 2023-219-19.5%Form 10-K (filed 2026-02-26) ↗
FY2022Dec 31, 2022-272-13.4%Form 10-K (filed 2025-02-27) ↗
FY2021Dec 31, 2021-314–Form 10-K (filed 2024-02-22) ↗

Cite this data

StockData. (2026). Pfizer Collaborative arrangements ($M), annual FY2021–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/collab-rd

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.